Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUXCOVID phase 3 study of ruxolitinib for COVID-19-associated cytokine storm
2020-001662-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS) comparing Ruxolitinib + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Composite clinical failure endpoint by Day 29. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2020-001662-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001662-11.